Mass Tort brief
J&J Talc Defense and Mesh Verdicts Reshape Mass Tort Dockets
A Massachusetts talc victory strengthens Johnson & Johnson's settlement leverage as federal courts refine bellwethers in hernia mesh, hair relaxer, and GLP-1 dockets.
Mass Tort
With over 12,000 cancer claims on file, the hair relaxer litigation faces a make-or-break November hearing over whether scientific evidence reaches a jury.
BackgroundThe National Institutes of Health published landmark research linking endocrine-disrupting chemicals in chemical hair straighteners to uterine and endometrial cancers. Women predominantly of color filed thousands of failure-to-warn claims against cosmetics manufacturers including L'Oréal.
- Judge Rowland narrowed the bellwether trial pool to five representative cancer cases, with the first jury trials slated to begin in 2027.
- Defense counsel for L'Oréal and other cosmetics firms filed motions challenging the epidemiological methodology connecting chemical exposure to endocrine tumors.
- The court lifted discovery stays shielding second-wave cosmetic distributors, expanding coordinated document disclosures and deposition schedules through mid-2027 to capture supply-chain liability.
Mass Tort
A federal judge ruled GLP-1 stomach injury claims require objective stomach scans — culling thousands of unsupported Ozempic lawsuits ahead of trial.
BackgroundBlockbuster GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro transformed medical weight-loss and diabetes treatments. Patients filed thousands of injury lawsuits alleging drugmakers failed to adequately warn about severe stomach paralysis and optic nerve ischemia.
- Active stomach paralysis claims across MDL 3094 exceeded 4,025 lawsuits, while the newly formed NAION optic nerve track reached 247 actions.
- Judge Karen Spencer Marston ruled plaintiffs must submit gastric emptying scintigraphy scans, barring lawsuits relying exclusively on subjective nausea reports.
- Novo Nordisk and Eli Lilly are mounting general causation defenses, arguing gastroparesis is an underdiagnosed baseline complication of severe diabetes.
Mass Tort
J&J won a critical Massachusetts talc trial — securing powerful leverage to push its $5.5B settlement across 69,000 pending cancer lawsuits.
BackgroundJohnson & Johnson faces tens of thousands of product liability lawsuits alleging its talc-based baby powders contained asbestos fibers that triggered ovarian cancers and mesothelioma. After federal bankruptcy courts dismissed two subsidiary Chapter 11 reorganizations, J&J proposed a $5.5 billion out-of-court settlement.
- The Boston jury found that while J&J should have provided a product warning label, the talcum powder was not the proximate legal cause of the plaintiff's mesothelioma.
- In federal MDL 2738 in New Jersey, active individual claims reached 69,340 as plaintiffs' attorneys contest the adequacy of J&J's proposed $5.5 billion settlement pool.
- Defense attorneys are using the trial victory to pressure plaintiffs' leadership into accepting comprehensive prepackaged resolution terms before more individual trials go to a jury.
Mass Tort
An $88M jury verdict broke Medtronic's defense on Covidien hernia mesh — setting up a decisive January trial that could force a nationwide settlement.
BackgroundHernia repair mesh products utilize synthetic polymer scaffolds coated with protective collagen barriers to prevent visceral organ adhesions during patient healing. Patients in MDL 3029 allege Covidien marketed defective mesh barriers that eroded within days, causing catastrophic bowel obstructions.
- A Boston federal jury awarded $77 million to an injured plaintiff and $11 million to his spouse after finding Covidien concealed rapid collagen barrier degradation.
- The federal docket in the District of Massachusetts has expanded to more than 2,340 active product liability lawsuits over various Covidien mesh lines.
- The January 2027 bellwether trial will test company liability for systemic inflammatory tissue reactions, increasing settlement pressure on parent company Medtronic.
Mass Tort
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
